Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Compounds Discovered In Asia Expected To Enter Clinic In Three Years, Pfizer Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Outstanding talent and patient needs for Asians are the main reason to be in Asia, not cost, Pfizer R&D exec Mackay stressed at a Singapore press conference.

You may also be interested in...



Big Pharmas Come Together On TB, But Effort To Accelerate Development May Hit Speedbump From Lack Of Biomarkers

A new multi-pharma company collaboration is intended to dramatically speed development of new combination regimens for tuberculosis, but efforts to accelerate development may be hindered by the lack of biomarkers for TB

Pfizer, Lilly And Merck Strike Up Cancer Research Partnership In Asia

Eli Lilly, Pfizer and Merck - like many Big Pharma - are hoping to spur growth in the future by addressing unmet medical need in Asia's emerging markets. The three companies hope to accelerate research in addressing Asia's most-commonly diagnosed cancers with a non-competitive collaboration - perhaps the first of its kind in the region - to share data for the next several years

Pfizer Achieves Double Firsts With AAHRPP Status For Phase I Trials In Singapore

SINGAPORE - Pfizer became the first pharma company to be accredited by the U.S.-based Association for the Accreditation of Human Research Protection Programs for its Phase I Clinical Research Unit in Singapore

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070598

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel